Avid Bioservices Inc (CDMO)

[entdoc]

EZ, if you read that PII Pfizer report on figitumumab you can see there is smoke, or a smokescreen, but no fire. Who cares if response is dose related if the improvement is 3.4 months to PFS v.3.9 mo. ..."fIGF-1 appeared to be a marker for resistance to chemotherapy, with median PFS as low as 2.1 months for patients in the highest fIGF-1 quartile (P=0.11). Patients with elevated baseline fIGF-1 levels appeared particularly sensitive to figitumumab. Study findings showed that adding figitumumab (20 mg/kg) to chemotherapy in patients with high levels of fIGF-1 increased PFS, versus treatment with paclitaxel and carboplatin alone (by 3.4 months, 6 months vs. 2.6 months, respectively, P=0.001 for patients with fIGF-1 >0.6 ng/mL, and by 3.9 months, 6 months vs. 2.1 months, respectively, p=0.001, for patients with fIGF-1 >0.9 ng/mL). Pfizer should go back to tetracycline and marketing sure-winners.